The University of California, Irvine's (UCI) Gynecologic Oncology Fellowship program is requesting continued support for the fellowship training program which is in its 29th year. The training grant is administered by UCI's National Cancer Institute designated Chao Family Comprehensive Cancer Center. The Gynecologic Oncology Fellowship program is dedicated to training physician scientists in the sub-specialty of Gynecologic Oncology by providing multiple levels of interaction between basic and clinical scientists to facilitate the transfer and exchange of information. The fellowship program provides trainees with opportunities for the practical application of skills in the design and testing of scientific hypotheses. Trainees receive three years of research training, consisting of two years training in the basic sciences followed by one year of clinical/translational research training. There are 28 training faculty, made up of 16 basic scientists and 12 clinical researchers from 10 departments in the School of Biological Sciences and College of Medicine. Faculty mentors have research concentrations in the following areas: photomedicine, structural molecular biology, growth factors and signaling, cell transformation and carcinogenesis, cancer epidemiology and cancer genetics, cancer screening and prevention, and experimental therapeutics. Sixteen of the training faculty have active, peer-reviewed research grants. Support is requested for 5 postdoctoral fellowship positions. Competition is keen for the one to two available entry-level fellowship positions annually. Recruitment for the fellowship program draws from the 1,200 Obstetrics and Gynecology residency positions nationwide. Over 90% of the graduated fellows from the program have assumed academic faculty positions. Training features of the program include didactic coursework in the areas of responsible conduct of research, biostatistics and epidemiology, and cancer-related electives, national scientific meetings, and numerous other multi-disciplinary seminars, lectures and symposia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA060396-15
Application #
7497051
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1994-09-26
Project End
2011-06-30
Budget Start
2008-07-01
Budget End
2011-06-30
Support Year
15
Fiscal Year
2008
Total Cost
$300,201
Indirect Cost
Name
University of California Irvine
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92697
Wolford, Juliet E; Tewari, Krishnansu S (2018) Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. Expert Opin Drug Discov 13:445-457
Minion, Lindsey E; Tewari, Krishnansu S (2018) Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol 148:609-621
Pfaendler, Krista S; Chang, Jenny; Ziogas, Argyrios et al. (2018) Disparities in Adherence to National Comprehensive Cancer Network Treatment Guidelines and Survival for Stage IB-IIA Cervical Cancer in California. Obstet Gynecol 131:899-908
Wolford, Juliet E; Tewari, Krishnansu S (2017) Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology. J Gynecol Oncol 28:e74
Pfaendler, Krista S; Tewari, Krishnansu S (2016) Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 214:22-30
Eskander, Ramez N; Ali, Shamshad; Dellinger, Thanh et al. (2016) Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer 26:125-32
Longoria, Teresa C; Tewari, Krishnansu S (2016) Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol 12:1247-53
Parham, Groesbeck P; Mwanahamuntu, Mulindi H; Kapambwe, Sharon et al. (2015) Population-level scale-up of cervical cancer prevention services in a low-resource setting: development, implementation, and evaluation of the cervical cancer prevention program in Zambia. PLoS One 10:e0122169
Pfaendler, Krista S; Wenzel, Lari; Mechanic, Mindy B et al. (2015) Cervical cancer survivorship: long-term quality of life and social support. Clin Ther 37:39-48
Eskander, Ramez N; Tewari, Krishnansu S (2015) Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol 11:909-22

Showing the most recent 10 out of 25 publications